Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine, Capecitabine and Epirubicin as First-Line Therapy in Advanced Breast Cancer
2005-005681-36Phase 2Active
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- Feb 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, capecitabine and epirubicin in breast cancer, sponsored by San Luigi Gonzaga Hospital. Primary endpoint: Response rate. Started Feb 2006; status: active.
02
Drugs
vinorelbinecapecitabineepirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005681-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005681-36.